Merit Medical Systems, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US5898891040
USD
84.09
-0.3 (-0.36%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

677.12 k

Shareholding (Mar 2025)

FII

11.58%

Held by 150 FIIs

DII

31.13%

Held by 66 DIIs

Promoter

0.00%

How big is Merit Medical Systems, Inc.?

22-Jun-2025

As of Jun 18, Merit Medical Systems, Inc. has a market capitalization of $5.49 billion, with net sales of $1.39 billion and a net profit of $122.27 million over the last four quarters.

Market Cap: As of Jun 18, Merit Medical Systems, Inc. has a market capitalization of 5,490.35 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Merit Medical Systems, Inc. reported net sales of 1,385.62 million and a net profit of 122.27 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,379.36 million and total assets of 2,418.60 million.

Read More

What does Merit Medical Systems, Inc. do?

22-Jun-2025

Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures, with a market cap of approximately $5.49 billion and quarterly net sales of $354 million. Key financial metrics include a P/E ratio of 42.00 and a return on equity of 9.28%.

Overview:<BR>Merit Medical Systems, Inc. is a manufacturer and marketer of disposable medical devices used in interventional, diagnostic, and therapeutic medical procedures, operating in the Pharmaceuticals & Biotechnology industry with a small-cap market classification.<BR><BR>Financial Snapshot:<BR>- Net Sales: 354 Million (Quarterly Results - Mar 2025)<BR>- Net Profit: 30 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 5,490.35 Million (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 42.00<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.24<BR>- Return on Equity: 9.28%<BR>- Price to Book: 3.84<BR><BR>Contact Details:<BR>- Address: 1600 W Merit Pkwy, SOUTH JORDAN UT: 84095-2416<BR>- Tel: ['1 801 2531600', '1 801 2084167']<BR>- Fax: 1 801 2531652<BR>- Website: https://www.merit.com/

Read More

Should I buy, sell or hold Merit Medical Systems, Inc.?

22-Jun-2025

Who are in the management team of Merit Medical Systems, Inc.?

22-Jun-2025

As of March 2022, the management team of Merit Medical Systems, Inc. includes Mr. Fred Lampropoulos as Chairman, President, and CEO, with Ms. Lynne Ward and several Independent Directors on the Board, including Mr. A. Scott Anderson, Ms. Jill Anderson, Mr. Thomas Gunderson, and Dr. F. Ann Millner.

As of March 2022, the management team of Merit Medical Systems, Inc. includes Mr. Fred Lampropoulos, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the Board of Directors features Ms. Lynne Ward as a Director, along with several Independent Directors: Mr. A. Scott Anderson, Ms. Jill Anderson, Mr. Thomas Gunderson, and Dr. F. Ann Millner.

Read More

Is Merit Medical Systems, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Merit Medical Systems, Inc. is considered overvalued with a valuation grade of expensive, reflected by its high P/E ratio of 42 and underperformance of -15.36% year-to-date compared to the S&P 500's 13.30% return.

As of 17 October 2025, the valuation grade for Merit Medical Systems, Inc. has moved from fair to expensive, indicating that the stock is overvalued. The company exhibits a P/E ratio of 42, a Price to Book Value of 3.94, and an EV to EBITDA of 20.38, all of which suggest a premium valuation compared to its peers. <BR><BR>In comparison, Masimo Corp. has a significantly higher P/E ratio of 179.74, while Lantheus Holdings, Inc. presents a much lower P/E of 10.13, highlighting the disparity in valuations within the sector. The recent stock performance shows that Merit Medical has underperformed against the S&P 500 year-to-date, with a return of -15.36% compared to the S&P 500's 13.30%, reinforcing the notion that the stock may be overvalued at its current price.

Read More

Is Merit Medical Systems, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Merit Medical Systems, Inc. is in a mildly bearish trend, with mixed technical indicators showing short-term outperformance against the S&P 500 but a year-to-date underperformance.

As of 31 October 2025, the technical trend for Merit Medical Systems, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly chart but is mildly bearish on the monthly chart. Bollinger Bands indicate a mildly bullish stance weekly, while they are bearish monthly. Daily moving averages are mildly bearish, and the KST reflects a mildly bullish signal weekly but is mildly bearish monthly. There are no clear trends indicated by Dow Theory or OBV.<BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, returning 6.91% and 5.06% respectively, while it has underperformed over the longer term, with a year-to-date return of -8.53% compared to the S&P 500's 16.30%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 11.57

 
2

Low Debt Company with Strong Long Term Fundamental Strength

 
3

Flat results in Jun 25

4

With ROCE of 9.76%, it has a expensive valuation with a 3.37 Enterprise value to Capital Employed

5

High Institutional Holdings at 100%

6

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5,468 Million (Small Cap)

stock-summary
P/E

42.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.27

stock-summary
Return on Equity

8.65%

stock-summary
Price to Book

3.67

Revenue and Profits:
Net Sales:
382 Million
(Quarterly Results - Jun 2025)
Net Profit:
33 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.66%
0%
-6.66%
6 Months
-11.11%
0%
-11.11%
1 Year
-19.78%
0%
-19.78%
2 Years
15.65%
0%
15.65%
3 Years
15.13%
0%
15.13%
4 Years
32.8%
0%
32.8%
5 Years
51.38%
0%
51.38%

Merit Medical Systems, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
8.25%
EBIT Growth (5y)
45.11%
EBIT to Interest (avg)
11.57
Debt to EBITDA (avg)
1.15
Net Debt to Equity (avg)
0.24
Sales to Capital Employed (avg)
0.68
Tax Ratio
20.40%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
7.65%
ROE (avg)
7.50%
Valuation key factors
Factor
Value
P/E Ratio
42
Industry P/E
Price to Book Value
3.94
EV to EBIT
34.55
EV to EBITDA
20.38
EV to Capital Employed
3.37
EV to Sales
4.31
PEG Ratio
2.12
Dividend Yield
NA
ROCE (Latest)
9.76%
ROE (Latest)
9.28%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 115 Schemes (57.2%)

Foreign Institutions

Held by 150 Foreign Institutions (11.58%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 7.82% vs -0.08% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 8.31% vs 7.89% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "382.00",
          "val2": "354.30",
          "chgp": "7.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "80.60",
          "val2": "83.00",
          "chgp": "-2.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "6.80",
          "val2": "6.60",
          "chgp": "3.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.20",
          "val2": "-10.40",
          "chgp": "111.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "32.60",
          "val2": "30.10",
          "chgp": "8.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "122.40%",
          "val2": "143.30%",
          "chgp": "-2.09%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.07% vs 9.23% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 27.54% vs 26.71% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,354.40",
          "val2": "1,253.30",
          "chgp": "8.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "271.20",
          "val2": "223.20",
          "chgp": "21.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "32.90",
          "val2": "18.10",
          "chgp": "81.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.60",
          "val2": "-1.50",
          "chgp": "-6.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "120.40",
          "val2": "94.40",
          "chgp": "27.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "115.50%",
          "val2": "97.30%",
          "chgp": "1.82%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
382.00
354.30
7.82%
Operating Profit (PBDIT) excl Other Income
80.60
83.00
-2.89%
Interest
6.80
6.60
3.03%
Exceptional Items
1.20
-10.40
111.54%
Consolidate Net Profit
32.60
30.10
8.31%
Operating Profit Margin (Excl OI)
122.40%
143.30%
-2.09%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 7.82% vs -0.08% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 8.31% vs 7.89% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1,354.40
1,253.30
8.07%
Operating Profit (PBDIT) excl Other Income
271.20
223.20
21.51%
Interest
32.90
18.10
81.77%
Exceptional Items
-1.60
-1.50
-6.67%
Consolidate Net Profit
120.40
94.40
27.54%
Operating Profit Margin (Excl OI)
115.50%
97.30%
1.82%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 8.07% vs 9.23% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 27.54% vs 26.71% in Dec 2023

stock-summaryCompany CV
About Merit Medical Systems, Inc. stock-summary
stock-summary
Merit Medical Systems, Inc.
Pharmaceuticals & Biotechnology
Merit Medical Systems, Inc. is a manufacturer and marketer of disposable medical devices used in a range of interventional, diagnostic and therapeutic medical procedures. The Company operates in two segments: cardiovascular and endoscopy. The cardiovascular segment consists of cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases, and includes embolotherapeutic, cardiac rhythm management (CRM), electrophysiology (EP), and interventional oncology and spine devices. Its endoscopy segment consists of gastroenterology and pulmonology medical devices, which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Within its segments, the Company offers products focused in four product groups: peripheral intervention, cardiac intervention, interventional oncology and spine, and endoscopy.
Company Coordinates stock-summary
Company Details
1600 W Merit Pkwy , SOUTH JORDAN UT : 84095-2416
stock-summary
Tel: 1 801 25316001 801 2084167
stock-summary
Registrar Details